Polskie Radio covers a newer weight loss drug framed as the next step after Ozempic. Details on which drug are not given here.
Recap by typeshit. Full story at www.polskieradio.pl.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
The writer cites a Gallup survey putting about 11 percent of Americans on GLP-1s and argues the real share is likely higher, and wants use discussed openly.
11:37
A 63 year old creator walks through six months on tirzepatide and a 48 pound drop, sharing a personal account of the experience.
In 194 adults who moved from injectable semaglutide or tirzepatide to oral semaglutide, 40.7% lost at least 5% more in three months. Data shown at EASD, not yet peer reviewed.
The advisory committee voted to return six peptides barred in 2023, over FDA staff objections. The author argues the GLP-1 shortage proved compounders can deliver.
Loading…